Patient Information Leaflet: Information for the User
Sitagliptin/Metformin Grindeks 50 mg/850 mg film-coated tablets EFG
Sitagliptin/Metformin Grindeks 50 mg/1,000 mg film-coated tablets EFG
sitagliptin/metformin hydrochloride
Read this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
Sitagliptin/Metformin Grindeks contains two different medicines called sitagliptin and metformin.
They work together to control blood sugar levels in adult patients with a form of diabetes called “type 2 diabetes mellitus”. This medicine helps to increase the amount of insulin produced after a meal and reduces the amount of sugar produced by your body.
Together with diet and exercise, this medicine helps to lower your blood sugar levels. This medicine can be used alone or with certain other medicines for diabetes (insulin, sulfonylureas, or glitazones).
What is type 2 diabetes?
Type 2 diabetes is a condition where your body does not produce enough insulin and the insulin that your body produces does not work as well as it should. Your body may also produce too much sugar. When this happens, sugar (glucose) builds up in the blood. This can lead to serious medical problems, such as heart disease, kidney disease, blindness, and amputations.
Do not take Sitagliptin/Metformin Grindeks
Do not take this medicine if any of the above applies to you and consult your doctor about other ways to control your diabetes. If you are not sure, consult your doctor, pharmacist, or nurse before taking this medicine.
Warnings and precautions
There have been reports of pancreatitis in patients treated with this medicine (see section 4).
If you notice blisters on your skin, it may be a sign of a disease called bullous pemphigoid. Your doctor may ask you to stop taking Sitagliptin/Metformin Grindeks.
Risk of lactic acidosis
This medicine may cause a very rare but very serious side effect called lactic acidosis, especially if your kidneys are not working properly. The risk of developing lactic acidosis is also increased by uncontrolled diabetes, serious infections, prolonged fasting, alcohol intake, dehydration (see below), liver problems, and any medical condition in which a part of your body has a reduced supply of oxygen (such as severe and acute heart disease).
If any of the above applies to you, consult your doctor for further instructions.
Consult your doctor immediately if:
Stop taking Sitagliptina/Metformina Grindeks for a short period if you have a condition that may be associated with dehydration(significant loss of body fluids), such as severe vomiting, diarrhea, fever, heat exposure, or if you drink less fluid than normal. Consult your doctor for further instructions.
Stop taking Sitagliptin/Metformin Grindeks and contact a doctor or the nearest hospital immediately if you experience any of the symptoms of lactic acidosis, as this condition can lead to coma.
The symptoms of lactic acidosis include:
Lactic acidosis is a medical emergency and must be treated in a hospital.
Consult your doctor or pharmacist before taking this medicine:
If you need to undergo major surgery, you should stop taking this medicine during the procedure and for some time after. Your doctor will decide when you should stop taking this medicine and when you can restart it.
If you are not sure if any of the above applies to you, consult your doctor or pharmacist before taking this medicine.
During treatment with this medicine, your doctor will check your kidney function at least once a year or more frequently if you are an elderly person and/or if your kidney function is worsening.
Children and adolescents
Children and adolescents under 18 years should not use this medicine. It is not effective in children and adolescents aged 10 to 17 years. It is not known if this medicine is safe and effective when used in children under 10 years.
Other medicines and Sitagliptin/Metformin Grindeks
If you need to be given an injection of a contrast agent containing iodine, for example, in the context of an X-ray or scan, you should stop taking this medicine before the injection or at the time of the injection. Your doctor will decide when you should stop taking this medicine and when you can restart it.
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines. You may need more frequent blood glucose and kidney function tests, or your doctor may need to adjust the dose of this medicine. It is especially important to mention the following:
Taking Sitagliptin/Metformin Grindeks with alcohol
Avoid excessive alcohol intake while taking Sitagliptin/Metformin Grindeks, as this may increase the risk of lactic acidosis (see section “Warnings and precautions”).
Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. You should not take this medicine during pregnancy or while breast-feeding. See section 2, Do not take Sitagliptin/Metformin Grindeks.
Driving and using machines
The effect of this medicine on your ability to drive or use machines is negligible or non-existent. However, there have been reports of dizziness and drowsiness during treatment with sitagliptin, which may affect your ability to drive or use machines.
Taking this medicine with sulfonylureas or insulin may cause hypoglycemia, which may affect your ability to drive or use machines or work without a secure support.
Sitagliptin/Metformin Grindeks contains sodium
This medicine contains less than 23 mg of sodium (1 mmol) per tablet; this is essentially “sodium-free”.
Follow exactly the instructions for administration of this medicine given by your doctor. If you are not sure, consult your doctor or pharmacist again.
You should continue with the diet recommended by your doctor during treatment with this medicine and be careful to distribute your carbohydrate intake evenly throughout the day.
It is unlikely that treatment with this medicine alone will cause you to have low blood sugar (hypoglycemia). Low blood sugar can occur when this medicine is taken with a medicine that contains a sulfonylurea or with insulin, so your doctor may consider it necessary to reduce the dose of your sulfonylurea or insulin.
If you take more Sitagliptin/Metformin Grindeks than you should
If you take more than the prescribed dose of this medicine, contact your doctor immediately. Go to the hospital if you have symptoms of lactic acidosis such as feeling cold or unwell, nausea or vomiting, stomach pain, unexplained weight loss, muscle cramps, or rapid breathing (see section “Warnings and precautions”).
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, telephone 91 562 04 20, indicating the medicine and the amount taken.
If you forget to take Sitagliptin/Metformin Grindeks
If you miss a dose, take it as soon as you remember. If you do not remember until the time of your next dose, skip the missed dose and continue with your normal treatment schedule. Do not take a double dose of this medicine.
If you stop taking Sitagliptin/Metformin Grindeks
Keep taking this medicine for as long as your doctor recommends. It will help to control your blood sugar levels. Do not stop taking this medicine without first talking to your doctor. If you stop taking this medicine, your blood sugar levels may increase again.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.
STOP taking this medicine and consult your doctor immediately if you notice any of the following serious adverse effects:
This medicine may cause a very rare (affecting up to 1 in 10,000 people) but very serious adverse effect called lactic acidosis (see section "Warnings and Precautions"). If this happens to you, you must stop taking Sitagliptina/Metformina Grindeks and contact a doctor or the nearest hospital immediately, as lactic acidosis can lead to coma.
If you have a severe allergic reaction (frequency not known), including skin rash, hives, blisters on the skin/exfoliative dermatitis, and swelling of the face, lips, tongue, and throat that can cause difficulty breathing or swallowing, stop taking this medicine and consult your doctor immediately. Your doctor will prescribe a medicine to treat the allergic reaction and change the medicine for the treatment of diabetes.
Some patients who took metformin have experienced the following adverse effects after starting treatment with sitagliptina:
Frequent (may affect up to 1 in 10 people): low blood sugar, nausea, gas, vomiting
Uncommon (may affect up to 1 in 100 people): stomach pain, diarrhea, constipation, drowsiness
Some patients have experienced diarrhea, nausea, gas, constipation, stomach pain, or vomiting when starting treatment with the combination of sitagliptina and metformina (frequency classified as frequent).
Some patients have experienced the following adverse effects when taking this medicine with a sulfonylurea such as glimepirida:
Very frequent (may affect more than 1 in 10 people): low blood sugar levels Frequent: constipation
Some patients have experienced the following adverse effects while taking this medicine in combination with pioglitazone:
Frequent: swelling of hands or feet
Some patients have experienced the following adverse effects while taking this medicine in combination with insulin:
Very frequent: low blood sugar levels Uncommon: dry mouth, headache
Some patients have experienced the following adverse effects during clinical trials while taking sitagliptina alone (one of the medicines that contains this medicine) or during use after approval of this medicine or sitagliptina alone or with other diabetes medicines: Frequent: low blood sugar levels, headache, upper respiratory tract infection, nasal congestion or runny nose, and sore throat, arthrosis, pain in the arm or leg
Uncommon: dizziness, constipation, itching
Rare: reduction in platelet count
Frequency not known: kidney problems (which may require dialysis), vomiting, joint pain, muscle pain, back pain, interstitial lung disease, bullous pemphigoid (a type of skin blister)
Some patients have experienced the following adverse effects after taking metformina alone:
Very frequent: nausea, vomiting, diarrhea, stomach pain, and loss of appetite. These symptoms may appear when you start taking metformina and usually disappear
Frequent: metallic taste, decreased or low vitamin B12 levels in blood (symptoms may include extreme fatigue, pain, and redness of the tongue, numbness or pale or yellowish skin). Your doctor may request tests to determine the cause of your symptoms because some of them may also be caused by diabetes or other unrelated health problems.
Very rare: hepatitis (liver problem), hives, skin redness (rash), or itching
Reporting Adverse Effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that does not appear in this prospectus. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of sight and reach of children.
This medicine does not require special storage conditions.
Do not use this medicine after the expiration date that appears on the blister pack and on the packaging after CAD. The expiration date is the last day of the month indicated.
Medicines should not be thrown away through wastewater or household waste. Deposit the packaging and medicines you no longer need at the SIGRE collection point in the pharmacy. Ask your pharmacist how to dispose of the packaging and medicines you no longer need. This way, you will help protect the environment.
Composition of Sitagliptina/Metformina Grindeks
Each film-coated tablet contains sitagliptina hydrochloride monohydrate equivalent to 50 mg of sitagliptina and 850 mg of metformina hydrochloride.
Each film-coated tablet contains sitagliptina hydrochloride monohydrate equivalent to 50 mg of sitagliptina and 1,000 mg of metformina hydrochloride.
Core of the tablet: povidone, sodium lauryl sulfate, microcrystalline cellulose, sodium stearyl fumarate.
Coating:
50 mg/850 mg tablets:
Macrogol copolymer of grafted polyethylene glycol and polyvinyl alcohol (E-1209)
Talc (E-553b)
Titanium dioxide (E-171)
Monoglycerides of fatty acids (E-471)
Polyvinyl alcohol (E-1203)
Yellow iron oxide (E-172)
Red iron oxide (E-172)
50 mg/1,000 mg tablets:
Macrogol copolymer of grafted polyethylene glycol and polyvinyl alcohol (E-1209)
Talc (E-553b)
Titanium dioxide (E-171)
Monoglycerides of fatty acids (E-471)
Polyvinyl alcohol (E-1203)
Red iron oxide (E-172)
Yellow iron oxide (E-172)
Black iron oxide (E-172)
Appearance of the Product and Package Contents
Sitagliptina/Metformina Grindeks is available in blister packs containing 28, 56, 98 film-coated tablets or in a multiple pack containing 196 (2 packs of 98) film-coated tablets.
Only some package sizes may be marketed.
Marketing Authorization Holder and Manufacturer
AS GRINDEKS.
Krustpils iela 53
Riga, LV-1057
Latvia
Phone: +371 67083205
Fax: +371 67083505
Email: grindeks@grindeks.com
You can request more information about this medicine by contacting the local representative of the marketing authorization holder
Grindeks Kalceks España, S.L.
C/ José Abascal, 58 – 2º Dcha.
Madrid, 28003, Spain
This medicine is authorized in the member states of the European Economic Area with the following names:
Sweden | Sitagliptin/Metformin Grindeks |
Austria | Sitagliptin/Metformin Grindeks 50 mg/850 mg, 50 mg/1000 mg Filmtabletten |
Belgium | Sitagliptin/Metformin Grindeks 50 mg/850 mg, 50 mg/1000 mg comprimés pelliculés |
Bulgaria | ???????????/????????? ???????? 50 mg/850 mg, 50 mg/1000 mg ????????? ???????? Sitagliptin/Metformin Grindeks 50 mg/850 mg, 50 mg/1000 mg film-coated tablets |
Croatia | Sitagliptin/Metformin Grindeks 50 mg/850 mg, 50 mg/1000 mg filmom obložene tablete |
Czech Republic | Sitagliptin/Metformin Grindeks |
Denmark | Sitagliptin/Metforminhydrochlorid Grindeks 50 mg/850 mg, 50 mg/1000 mg filmovertrukne tabletter |
Estonia | Metformin/Sitagliptin Grindeks |
Finland | Sitagliptin/Metformin Grindeks 50 mg/850 mg, 50 mg/1000 mg kalvopäällysteiset tabletit |
France | SITAGLIPTINE/METFORMINE GRINDEKS 50 mg/850 mg, comprimé pelliculé SITAGLIPTINE/METFORMINE GRINDEKS 50 mg/1000 mg, comprimé pelliculé |
Germany | Sitagliptin/Metformin Grindeks 50 mg/850 mg, 50 mg/1000 mg Filmtabletten |
Greece | Sitagliptin/Metformin Grindeks 50 mg/850 mg, 50 mg/1000 mg επικαλυμμ?να με λεπτ? υμ?νιο δισκ?α |
Hungary | Sitagliptin/Metformin Grindeks 50 mg/850 mg, 50 mg/1000 mg filmtabletta |
Ireland | Sitagliptin/Metformin Hydrochloride Grindeks 50 mg/850 mg, 50 mg/1000 mg film-coated tablets |
Italy | Sitagliptin/Metformina Grindeks |
Latvia | Sitagliptin/Metformin Grindeks 50 mg/850 mg, 50 mg/1000 mg apvalkotas tabletes |
Lithuania | Sitagliptin/Metformin hydrochloride Grindeks 50 mg/850 mg, 50 mg/1000 mg plevele dengtos tabletes |
Luxembourg | Sitagliptin/Metformin Grindeks 50 mg/850 mg, 50 mg/1000 mg filmbeschichtete Pëllen |
Netherlands | Sitagliptine/Metformine Grindeks 50 mg/850 mg, 50 mg/1000 mg filmomhulde tabletten |
Norway | Sitagliptin/Metformin Grindeks |
Poland | Sitagliptin + Metformin Grindeks |
Portugal | Metformina + Sitagliptina Grindeks 850 mg + 50 mg, 1000 mg + 50 comprimidos revestidos por película |
Romania | Sitagliptina/Metformin Grindeks 50 mg/850 mg, 50 mg/1000 mg comprimate filmate |
Slovakia | Sitagliptin/Metformin Grindeks 50 mg/850 mg, 50 mg/1000 mg filmom obalené tablety |
Slovenia | Sitagliptin/metforminijev klorid Grindeks 50 mg/850 mg, 50 mg/1000 mg filmsko obložene tablete |
Spain | Sitagliptina/Metformina Grindeks 50 mg/850 mg, 50 mg/1,000 mg comprimidos recubiertos con película EFG |
Date of the Last Revision of this Prospectus:April2025
Detailed information about this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) (http://www.aemps.gob.es/)